返回
C
Cristina Saura
fondazione irccs istituto nazionale tumori
61H指数
740论文数
1.9W被引数
收录论文 217
发表时间
Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]人表皮生长因子受体2(HER2)阳性乳腺癌患者中的术后放疗:辅助拉帕替尼和/或曲妥珠胺治疗优化(ALTTO)试验(BIG 2-06/NCCTG N063D(Alliance))的回顾性探索性队列分析
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03来自DESTINY-Breast01,DESTINY-Breast02和DESTINY-Breast03的HER2-positive转移性乳腺癌患者对曲妥珠单抗deruxtecan和相关生物标志物的最佳确认反应的汇总分析
Annals of Oncology
IF65.4
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02Tucatinib和trastuzumab emtansine用于既往治疗过的HER2阳性局部晚期和转移性乳腺癌患者:随机III期试验HER2CLIMB-02的主要分析
Annals of Oncology
IF65.4
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial出版物简明摘要:比较在CheckMate 7FL临床试验中,对于新诊断的雌激素受体阳性乳腺癌患者,使用纳武利尤单抗联合新辅助化疗与安慰剂联合新辅助化疗的疗效。
FUTURE ONCOLOGY
IF2.6
Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]勘误:“Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]
The Breast
IF0
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a studyZanidatamab联合palbociclib和fulvestrant治疗既往接受过治疗的激素受体阳性、HER2阳性转移性乳腺癌:一项两阶段、多中心、单臂、2a期研究的主要结果

